NEUROCRINE BIOSCIENCES INC
StreetZero Signal 62
About NEUROCRINE BIOSCIENCES INC
Neurocrine Biosciences, Inc. is a public biotechnology company focused on discovering and developing treatments for central nervous system and endocrine-related disorders. Founded in 1992 and headquartered in San Diego, California, the company operates as a B2B pharmaceutical developer with lead programs including elagolix. It is listed on NASDAQ under the ticker NBIX and maintains a website at www.neurocrine.com.
LATEST FUNDINGRule 144
$2.5M
Announced 2026-11-17
TOTAL RAISED$1.29B
IN THE NEWS
- ๐ Neurocrine Biosciences
- ๐ Neurocrine Biosciences, Inc. Announces Proposed Public Offering of Common Stock
- ๐ Neurocrine Biosciences Inc (NBIX) Financial Statements -- TradingKey
- ๐ Decoding Neurocrine Biosciences Inc (NBIX): A Strategic SWOT Insight
- ๐ Neurocrine Biosciences, Inc. (NBIX) Stock Price, News, Quote & History - Yahoo Finance
EMPLOYEES2500
FOUNDED1992
HQSan Diego, California, United States
Industry
Public Equity (NASDAQ)
Tags
BiotechnologyPublic CompanyNASDAQPharmaceuticals
Investors
Key highlights
- Publicly traded on NASDAQ (NBIX) with over 1.29B USD raised historically.
- Completed a $2,479,650 Rule 144 placement.
- Last major round was 1.00B USD post-IPO debt in 2026.
- Focuses on CNS and endocrine drug development with partnerships such as AbbVie.
- Reports strong financial metrics including 3.70B USD revenue and positive EPS growth.
Ask StreetZero about NEUROCRINE BIOSCIENCES INC
Put our AI to work on this deal.
Similar companies
Other Public Equity (NASDAQ) deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account